Certepetide is under clinical development by Lisata Therapeutics and currently in Phase II for Recurrent Head And Neck Squamous Cell Carcinoma. According to GlobalData, Phase II drugs for Recurrent Head And Neck Squamous Cell Carcinoma have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Certepetide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Certepetide (CEND-1) is under development for the treatment of solid tumors such as pancreatic cancer including pancreatic ductal adenocarcinoma, gastroesophageal junction carcinomas, triple-negative breast cancer, appendiceal cancer, breast cancer, recurrent head and neck cancer squamous cell carcinoma, appendiceal cancer oropharyngeal cancer, oral cavity (mouth) cancer, hypopharyngeal cancer, laryngeal cancer, peritoneal carcinoma, colon cancer, ovarian cancer, esophageal squamous cell carcinoma, bile duct cancer (cholangiocarcinoma), gastric cancer, adenocarcinoma of the gastroesophageal junction, glioblastoma multiforme, peritoneal carcinomatosis and metastatic colorectal cancer. The drug candidate is an internalized-arginylglycylaspartic acid cyclic peptide which acts by targeting neuropilin 1 receptor. It is administered through the intravenous route and is developed based on CendR Platform.
It was also under development for breast cancer, prostate cancer, non-small cell lung cancer, glioblastoma, hepatocellular carcinoma, Esophageal Squamous Cell Carcinoma (ESCC) and ovarian cancer.
Lisata Therapeutics overview
Lisata Therapeutics, formerly Caladrius Biosciences Inc, is a biopharmaceutical company. It discovers and develops cellular therapies for the treatment of cardiovascular indications and autoimmune diseases. It is investigating XOWNA for the treatment of coronary microvascular dysfunction; HONEDRA against critical limb ischemia and buerger’s disease. The company is also evaluating CLBS201 for the treatment of diabetic kidney disease (DKD); and CLBS14 to treat no-option refractory disabling angina. Lisata Therapeutics utilizes its proprietary CD34+ cell therapy technology to develop therapies for ischemia diseases. It serves biotechnology, pharmaceutical and medical product companies, and academic research institutions. Lisata Therapeutics is headquartered in Basking Ridge, New Jersey, the US.
For a complete picture of Certepetide’s drug-specific PTSR and LoA scores, buy the report here.